Emovi
Emovi is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Emovi.
Emovi is a company.
Key people at Emovi.
Emovi is a Montreal-based medtech company developing AI-powered medical devices for joint assessment, primarily the KneeKG system—the first in-clinic technology to measure 3D dynamic knee alignment with objective data.[1][5][6] It serves orthopedic surgeons, sports medicine physicians, radiologists, family doctors, elite sports teams, and military organizations by solving inefficiencies in knee diagnostics, enabling better triage for total knee arthroplasty (TKA), personalized treatment plans, and improved patient outcomes like reduced pain and restored function at a fraction of MRI costs.[1][4][5] With FDA, Health Canada, and CE approvals, KneeKG is commercialized in 10 countries, backed by multiple patents and a $15M Series C raise in 2019, driving growth through clinical adoption and partnerships.[4][5]
Founded in 2007 and headquartered in Laval, Quebec, Canada, Emovi emerged from collaborations with Quebec universities like CRCHUM, École de Technologie Supérieure (ETS), and TELUQ to develop KneeKG.[1][6] Early efforts from 2012-2017 focused on pre-commercialization testing at academic centers, validating efficacy through publications despite challenges like EMR integrations and compliance.[4] Pivotal support came from investors like Desjardins-Innovatech and CTS Santé, enabling market entry; leadership under President & CEO Michelle Laflamme has steered it toward global commercialization.[3][4] Chief Scientific and Technology Officer Alex Fuentes highlights the team's drive from "Emotion • Movement • Vision" to empower active lifestyles.[1][5]
Emovi rides the wave of AI-driven precision orthopedics and value-based care, addressing rising knee osteoarthritis demands amid aging populations and sports injuries.[1][5] Timing aligns with post-COVID supply chain resilience—its Quebec-based production maintained independence—while regulatory approvals (FDA, CE Class II) and global reach (10 countries) capitalize on medtech's shift to functional, data-rich diagnostics over costly scans.[4][5] It influences ecosystems by triaging patients, cutting program costs, and advancing population health, partnering with research institutions and militaries to set standards for joint kinesiography and expand to hip/shoulder assessments.[1][5]
Emovi's trajectory points to scaled adoption in sports, military, and orthopedics, with AI enhancements and new joints (hip, shoulder) fueling revenue amid growing demand for preventive biomechanics.[5] Trends like AI personalization and telehealth will amplify KneeKG's edge, potentially evolving Emovi into a multi-joint platform leader. As it builds on its $15M momentum, expect deeper U.S./European penetration and partnerships, solidifying its role in efficient, outcome-focused knee care.[4][5]
Key people at Emovi.
